Clinical Trials Logo
  1. Home
  2. Pneumonia, Viral
  3. NCT04727775
  4. Details
NCT04727775 Clinical Trial

Antiviral Drugs on the Treatment of SARS-CoV-2

Pneumonia, Viral Clinical Trial

— FavRem  

Official title:
A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04727775
Other study ID # AMU
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2020
Est. completion date July 25, 2023

Study information
Verified date August 2023
Source Astana Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Description:

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

Recruitment information / eligibility
Status Completed
Enrollment 150
Est. completion date July 25, 2023
Est. primary completion date July 25, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: main group - Patients with COVID19 with medium and easy condition disease - take favipiravir/remdisivir control group - Patients with COVID19 with medium and easy condition disease - not take favipiravir/remdisivir Exclusion Criteria: - patients younger 18 - severe conditionis

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Favipiravir
Antiviral drugs
• Remdesivir
Antiviral drugs

Locations
Country Name City State
Kazakhstan Aidos Konkaev Astana
Kazakhstan Semey Medical University Semey

Sponsors (1)
Lead Sponsor Collaborator
Astana Medical University

Country where clinical trial is conducted

Kazakhstan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Outcome without comlications The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2 14 days
Secondary Heart rate Measure 14 days
Secondary SpO2 Measure 14 days
Secondary Blood pressure Measure 14 days
Secondary Respiratory rate Measure 14 days
See also
  Status Clinical Trial Phase
Completed NCT04517123 - Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study N/A
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed NCT01271842 - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study N/A
Completed NCT04724538 - Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19 Phase 1/Phase 2
Recruiting NCT04414293 - Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis N/A
Completed NCT04047719 - Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Recruiting NCT04528888 - Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Phase 3
Completed NCT04606407 - Inhaled NO for the Treatment of Viral Pneumonia in Adults N/A
Terminated NCT04619693 - Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
Recruiting NCT05077917 - Cromolyn Sodium for Treatment of COVID-19 Pneumonia Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT05976581 - Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients N/A
Active, not recruiting NCT04381364 - Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) Phase 2
Completed NCT04422613 - Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia N/A
Completed NCT04479540 - Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease N/A
Recruiting NCT04474340 - COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients Phase 1
Completed NCT04424836 - HFNC Treatment in COVID-19 Pneumonia
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04387799 - Determinants of COVID-19 Pneumonia (MC-19)
Completed NCT04382547 - Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Phase 1/Phase 2